Related Experiment Videos
Pemphigus vulgaris treated with combined oral cyclosporin and cyclophosphamide
Clinical and Experimental Dermatology
|August 6, 1998
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Adult coronary artery disease probably due to childhood Kawasaki disease.
Lancet (London, England)·1992
Human luteal cells express dipeptidyl peptidase IV on the cell surface.
The Journal of clinical endocrinology and metabolism·1992
The Impact of Male Genital Dermatology in the Field of Andrology.
Clinical and experimental dermatology·2026
Pigmented Actinic Lichen Planus Mimicking Chronic Photodermatitis in a Fair-Skinned Caucasian Woman: A Case Report.
Clinical and experimental dermatology·2026
Extramammary Paget's Disease With Bilateral Sentinel Lymph Node Biopsy: a Multicenter Study of Lymphatic Patterns and Outcomes.
Clinical and experimental dermatology·2026
Outcome selection and reporting transparency in ClinicalTrials.gov-registered chronic spontaneous urticaria trials: a registry-publication linkage study.
Clinical and experimental dermatology·2026
Real-time assessment of mitotic rate in malignant melanoma by ex vivo confocal microscopy.
Clinical and experimental dermatology·2026
Tumour-Vascular Interface in melanomas with Breslow thickness ≥0.8 mm: A Confocal Microscopy Study.
Clinical and experimental dermatology·2026
Time to Treatment Failure as a Recorded Treatment-Process Measure in C-CAT. Reply to Comment on "Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462".
Current oncology (Toronto, Ont.)·2026
Does Time to Treatment Failure Measure the Same Clinical Process Across Oncology Facilities? Comment on Kajiura et al. Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462.
Current oncology (Toronto, Ont.)·2026
[177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing.
Current oncology (Toronto, Ont.)·2026
A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies.
Current oncology (Toronto, Ont.)·2026